Clinical Trial

Mature B-Cell Lymphoma And Leukemia Study III

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a phase III clinical trial using risk-adapted therapy. Treatment outcomes for children with B-cell NHL are excellent. Further improvements in outcome will likely be achieved through more focused study of the biology of the tumors and prospective studies of the late effects of treatment. Toward this end, this study features a spectrum of prospective biologic and late effect studies performed in patients treated with a modified regimen derived from the very successful LMB-96 regimen.
Protocol Amendment History 32 amendments
This ClinicalTrials.gov record has been amended 32 times since 2010-01-11; most recent amendment 2026-05-15.
Status change: Recruiting → Active, Not Recruiting 2022-09-23
Trial Details
NCT Number NCT01046825
Lead Sponsor St. Jude Children's Research Hospital
Conditions Mature B-Cell Lymphoma
Enrollment 128 participants
Start Date 2010-09-09
Primary Completion 2023-08-31 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-02